The Current Ratio as of November 2024 (TTM) for Lineage Cell Therapeutics, Inc. (LCTX) is 2.64

According to Lineage Cell Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 2.64. This represents a change of 3.40% compared to the average of 2.56 of the last 4 quarters.

Lineage Cell Therapeutics, Inc. (LCTX) Historical Current Ratio (quarterly & annually)

How has LCTX Current Ratio performed in the past?

The mean historical Current Ratio of Lineage Cell Therapeutics, Inc. over the last ten years is 4.50. The current 2.64 Current Ratio has changed 5.78% with respect to the historical average. Over the past ten years (40 quarters), LCTX's Current Ratio was at its highest in in the June 2021 quarter at 10.58. The Current Ratio was at its lowest in in the September 2014 quarter at 1.72.

Lineage Cell Therapeutics, Inc. (LCTX) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Lineage Cell Therapeutics, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Lineage Cell Therapeutics, Inc. (LCTX) Average Current Ratio

How has LCTX Current Ratio performed in the past?

The current Current Ratio of Lineage Cell Therapeutics, Inc. (LCTX) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Lineage Cell Therapeutics, Inc. (LCTX) Current Ratio vs. Peers

How is LCTX’s Current Ratio compared to its peers?

Lineage Cell Therapeutics, Inc.’s Current Ratio is less than MAIA Biotechnology, Inc. (3.42), greater than Armata Pharmaceuticals, Inc. (0.25), less than Frequency Therapeutics, Inc. (4.42), greater than Portage Biotech Inc. (1.73), greater than AgeX Therapeutics, Inc. (0.64), less than Cadrenal Therapeutics, Inc. Common Stock (3.60), greater than ImmuCell Corporation (2.37), less than Oxford Nanopore Technologies plc (4.45), less than Replimune Group, Inc. (13.46), less than Nuvectis Pharma, Inc. (3.17), less than Lyra Therapeutics, Inc. (3.60), less than Kronos Bio, Inc. (8.49), less than Gossamer Bio, Inc. (8.21), less than Neoleukin Therapeutics, Inc. (15.33), less than Nuvation Bio Inc. (11.49), less than Ovid Therapeutics Inc. (5.73), less than NextCure, Inc. (8.35), less than Connect Biopharma Holdings Limited (12.04), less than Spero Therapeutics, Inc. (2.68), less than Bolt Biotherapeutics, Inc. (4.28), greater than Coherus BioSciences, Inc. (1.21), less than Gracell Biotechnologies Inc. (7.73),

Build a custom stock screener for Lineage Cell Therapeutics, Inc. (LCTX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Lineage Cell Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Lineage Cell Therapeutics, Inc. (LCTX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Lineage Cell Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.